Literature DB >> 16009087

Complex regional pain syndrome: which treatments show promise?

Anna Quisel1, James M Gill, Peter Witherell.   

Abstract

Treatments for CRPS type 1 supported by evidence of efficacy and little likelihood for harm are: topical DMSO cream (B), IV bisphosphonates (A) and limited courses of oral corticosteroids (B). Despite some contradictory evidence, physical therapy and calcitonin (intranasal or intramuscular) are likely to benefit patients with CRPS type 1 (B). Due to modest benefits and the invasiveness of the therapies, epidural clonidine injection, intravenous regional sympathetic block with bretylium and spinal cord stimulation should be offered only after careful counseling (B). Therapies to avoid due to lack of efficacy, lack of evidence, or a high likelihood of adverse outcomes are IV regional sympathetic blocks with anything but bretylium, sympathetic ganglion blocks with local anesthetics, systemic IV sympathetic inhibition, acupuncture, and sympathectomy (B).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009087

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  4 in total

1.  Give vitamin C to avert lingering pain after fracture.

Authors:  James J Stevermer; Bernard Ewigman
Journal:  J Fam Pract       Date:  2008-02       Impact factor: 0.493

Review 2.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

3.  Conservative therapy for Complex Regional Pain Syndrome Type I in a paediatric patient: a case study.

Authors:  Randy W Beck
Journal:  J Can Chiropr Assoc       Date:  2009

4.  CT-guided stellate ganglion blockade vs. radiofrequency neurolysis in the management of refractory type I complex regional pain syndrome of the upper limb.

Authors:  Adrian Kastler; Sébastien Aubry; Nicolas Sailley; Demosthene Michalakis; Gaye Siliman; Guillaume Gory; Jean-Louis Lajoie; Bruno Kastler
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.